3 results
Approved WMOCompleted
The primary objective of the study is to evaluate the effect of 48 hours of intravenous (IV) omecamtiv mecarbil compared with placebo on dyspnea in subjects with left ventricular systolic dysfunction hospitalized for acute heart failure.Secondary:*…
Approved WMOCompleted
The primary objectives of this study are to select an oral modified release (MR) formulation and dose of omecamtiv mecarbil for in subjects with HF and left ventricular systolic dysfunction and to characterize itspharmacokinetics (PK) after 20 weeks…
Approved WMOCompleted
To investigate whether using the ARC during 166Ho-RE increases the post-treatment tumor to non-tumor (T/N) activity concentration ratio, compared to using a standard end-hole microcatheter.